Recombinant Human c-MET/HGFR Protein (C-His)

Measured by functional ELISA. Immobilized recombinant human c-MET ECD binds recombinant human HGF with an EC50 in the ng/mL range; binding is blocked by reference anti-c-MET antibodies.

c-MET (hepatocyte growth factor receptor, HGFR) is a receptor tyrosine kinase whose misregulation — exon 14 skipping, amplification or overexpression — is a defined oncogenic driver in NSCLC, gastric cancer and other malignancies. Normally, HGF binding to the extracellular SEMA and PSI domains triggers scattering, invasion and branched morphogenesis during tissue repair; in cancer the same program becomes invasive growth and therapy resistance. The MET arena now spans highly selective TKIs (capmatinib, tepotinib, savolitinib), MET-directed antibodies and antibody–drug conjugates, all of which require reliable extracellular-domain reagents for ligand-blocking, receptor occupancy and pharmacodynamic assays. This ECD construct covers the full HGF-binding ectodomain for those applications.